Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes

Cancer Research

Volumn 61, Issue 24, 2001, Pages 8751-8757

  McCart, J Andrea ^a   Ward, Jerrold M ^a,c   Lee, John ^a   Hu, Yun ^a   Alexander, H Richard ^a   Libutti, Steven K ^a   Bartlett, David L ^a   Moss, Bernard ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; GROWTH FACTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG; VACCINIA GROWTH FACTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; GENE DELETION; GENE INSERTION; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; VACCINIA VIRUS; VIRUS MUTANT; VIRUS PATHOGENESIS;

3T3 CELLS; ANIMALS; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; GENE DELETION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HAPLORHINI; HELA CELLS; HUMANS; LUMINESCENT PROTEINS; MICE; MICE, INBRED C57BL; MICE, NUDE; PEPTIDES; POXVIRIDAE INFECTIONS; THYMIDINE KINASE; TUMOR CELLS, CULTURED; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 0035893770     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells
2. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector
3. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism
4. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma
5. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors
6. Replicating viruses as selective cancer therapeutics
7. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression
8. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
9. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy
10. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207
11. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor specific gene expression and prolongation of survival in mice
12. Thymidine kinase deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor directed gene therapy
13. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
14. Experimental therapy of human glioma by means of a genetically engineered virus mutant
15. Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting
16. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
17. Results of a Phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer
18. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate
19. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T lymphocytes
20. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF
21. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules
22. In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1β
23. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12
24. Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2
25. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection
26. Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity
27. Risks of smallpox vaccination complications in the United States
28. A fatal case of progressive vaccinia-clinical and pathological studies
29. Vaccinia necrosum complicating immunoblastic sarcoma
30. Progressive vaccinia associated with combined variable immunodeficiency
31. Vaccinia virus in postvaccinal encephalitis
32. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype
33. Deletion of the vaccinia virus growth factor gene reduces virus virulence
34. Vaccinia virus for human gene therapy
35. Vaccinia as a vector for tumor directed gene therapy: Biodistribution of a thymidine kinase deleted mutant
36. Regional verses systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases
37. Cell proliferative response to vaccinia virus is mediated by VGF
38. Envelope formation is blocked by mutation of a sequence related to the HKD phospholipid metabolism motif in the vaccinia virus F13L protein
39. Compact, synthetic, vaccinia virus early/late promoter for protein expression
40. Simple and rapid preparation of samples for PCR
41. Expression of proteins in mammalian cells using vaccinia viral vectors
42. Endostatin. An endogenous inhibitor of angiogenesis and tumor growth
43. Non-parametric estimation from incomplete observation
44. Evaluation of survival data and two new rank order statistics arising in its consideration
45. Poxviruses as expression vectors
46. Infectious poxvirus vectors have capacity for at least 25, 000 base pairs of foreign DNA
47. Structure of vaccinia virus early promoters
48. Structure of vaccinia virus late promoters
49. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperperme-ability of tumor blood vessels
50. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis
51. Angiogenesis in the corpus luteum
52. A replication competent recombinant vaccinia vector expressing HSV-TK for the treatment of tumors in vivo
53. The pathogenesis, pathology, and immunology of orthopoxvirus infections
54. Vaccinia virus-mediated damage of murine ovaries and protection by virus-expressed interleukin-2
55. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
56. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation
57. Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma
58. Poly (lactic-glycolic) acid co-polymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo
59. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro
60. Human gene marker/therapy clinical protocols